ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Target Raised at Canaccord Genuity Group

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its target price upped by Canaccord Genuity Group from $36.00 to $38.00 in a report issued on Friday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also issued reports on ACAD. TD Cowen reaffirmed a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, September 24th. Weiss Ratings upgraded ACADIA Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, August 12th. Deutsche Bank Aktiengesellschaft reduced their price objective on ACADIA Pharmaceuticals from $38.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, September 25th. Oppenheimer restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Wednesday, September 23rd. Finally, HC Wainwright decreased their price objective on ACADIA Pharmaceuticals from $37.00 to $33.00 and set a “buy” rating on the stock in a report on Friday, September 25th. Thirteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.55.

ACADIA Pharmaceuticals Price Performance

NASDAQ ACAD traded down $0.01 on Friday, hitting $21.23. The company had a trading volume of 1,770,847 shares, compared to its average volume of 1,531,452. The company’s fifty day moving average price is $22.86 and its 200-day moving average price is $23.59. The company has a market capitalization of $3.66 billion, a PE ratio of 10.06 and a beta of 0.87. ACADIA Pharmaceuticals has a 12-month low of $18.39 and a 12-month high of $30.96.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.11. The business had revenue of $342.30 million for the quarter, compared to the consensus estimate of $332.58 million. ACADIA Pharmaceuticals had a net margin of 33.42% and a return on equity of 9.03%. The company’s revenue was up 22.8% compared to the same quarter last year. During the same period last year, the firm posted $0.42 earnings per share. On average, sell-side analysts anticipate that ACADIA Pharmaceuticals will post 0.66 EPS for the current year.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, EVP Mark Schneyer sold 3,321 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $20.88, for a total value of $69,342.48. Following the transaction, the executive vice president directly owned 71,322 shares of the company’s stock, valued at $1,489,203.36. This trade represents a 4.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 26.20% of the company’s stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in ACADIA Pharmaceuticals during the second quarter worth approximately $569,634,000. First Trust Advisors LP boosted its stake in ACADIA Pharmaceuticals by 47.3% during the first quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock worth $74,435,000 after buying an additional 1,073,834 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in ACADIA Pharmaceuticals by 8.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company’s stock valued at $70,222,000 after buying an additional 234,186 shares in the last quarter. Palo Alto Investors LP purchased a new stake in ACADIA Pharmaceuticals in the 2nd quarter valued at $72,461,629. Finally, Renaissance Technologies LLC increased its stake in shares of ACADIA Pharmaceuticals by 12.5% in the 1st quarter. Renaissance Technologies LLC now owns 1,724,196 shares of the biopharmaceutical company’s stock worth $38,381,000 after acquiring an additional 191,600 shares during the last quarter. 96.71% of the stock is currently owned by hedge funds and other institutional investors.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: RBC raised its price target to $41 from $31 and maintained an Outperform rating, citing continued momentum for Daybue. RBC price-target update RBC Daybue commentary
• Positive Sentiment: Canaccord Genuity raised its target to $38 from $36 and reiterated a Buy rating, adding to the favorable analyst outlook. Canaccord analyst recommendations
• Positive Sentiment: ACADIA reported Q3 revenue of $342.3 million, above the roughly $332.6 million consensus, and earnings of $0.31 per share, ahead of estimates around $0.19–$0.20. Revenue increased 22.8% year over year, reinforcing the company’s growth story. Q3 earnings results
• Neutral Sentiment: The company revised its 2026 earnings guidance, but the provided report headline does not disclose the direction or magnitude of the change. Investors will need the detailed guidance to assess its implications. 2026 earnings guidance update

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system and neuropsychiatric disorders. The company’s research programs target conditions with significant unmet medical needs, including neurological and rare neurodevelopmental diseases.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis.